Neutrophil-lymphocyte ratio across psychiatric diagnoses: An electronic health record investigation

Introduction

Inflammation is a key component of our immune response to physiological injury or infection (Xiao, 2017). Low-grade systemic inflammation is an attenuated, but persistent, form of the inflammatory response and has been found to be prevalent across a range of psychiatric diagnoses, including psychotic, mood, neurotic, and personality, disorders (Osimo et al, 2018).

Blood biomarkers are the most commonly used method to study inflammatory processes in psychiatry (Fond et al, 2018, Pinto et al, 2017), but many of these are costly or difficult to collect routinely. The neutrophil to lymphocyte ratio (NLR) can be calculated from a full blood count and is thus cheaper and more readily available than cytokine testing (Gibson et al, 2007). NLR has been suggested to be a marker of the intensity of physiological stress present in acutely ill patients, and a measure of systemic inflammation (Zahorec, 2001). As it constitutes parameters from both innate (neutrophil) and adaptive (lymphocyte) immune systems, it may be less affected by confounding variables, such as exercise, compared to other commonly used inflammatory biomarkers (Gibson et al, 2007). NLR has demonstrated reliable prognostic value across a range of physical health disorders (Afari & Bhat, 2016, Chandrashekara et al, 2017, Koh et al, 2015, Wang et al, 2017), highlighting a positive association between systemic inflammation and worse clinical outcomes.

The most studied inflammatory biomarkers in psychiatry, interleukin-6 (IL-6), tumour necrosis factor (TNF) and c-reactive protein (CRP), are elevated in patients with schizophrenia, bipolar disorder and depression, compared to controls (Pinto et al, 2017). NLR also appears to be elevated in major psychiatric disorders compared to controls (Karageorgiou et al, 2018, Mazza et al, 2018, Mazza et al, 2019a). However, the vast proportion of studies have studied a single disorder in comparison to healthy controls, or at best, two different psychiatric disorders (Pinto et al, 2017). True transdiagnostic studies are rare with only three studies to date comparing NLR between psychiatric diagnoses (Baykan et al, 2018, Mazza et al, 2019b, Ozdin et al, 2017).

Of the NLR studies comparing different psychiatric diagnoses, Ozdin et al (2017) reported that patients with schizophrenia, experiencing a psychotic episode, had higher NLR than patients with manic-phase bipolar disorder (BD), suggesting there are detectable differences in NLR across diagnosis and symptomatology. Mazza et al (2019b) found patients with manic-phase BD had higher NLR than patients with major depressive disorder (MDD). They also found significant differences between manic-phase and depressive-phase BD but not between depressive-phase BD and MDD suggesting that NLR may be elevated in mania but not depression. Lastly, Baykan et al (2018) found NLR to be significantly elevated in elderly patients with Alzheimer’s (AD), compared to elderly patients with MDD. Shared symptomatology between AD and MDD is problematic for clinicians differentiating between the disorders (Baykan et al, 2018) and the authors suggested that NLR may be an effective diagnostic marker to aid discrimination.

The current evidence base is limited and inconsistent. Further research is required to investigate the role of inflammatory processes in psychiatric illness. Differentially elevated inflammation between different diagnoses may suggest inflammatory processes are more common in specific disorders. Alternatively, comparable elevation between diagnoses may suggest common aetiological pathways, such as shared immunological genetic vulnerabilities and inflammatory processes. Patients with elevated NLR may represent a subtype of psychiatric illness that does not fit within current diagnostic categories. Lastly, systemic inflammation may be a by-product of mental health difficulties, reflecting a non-specific comorbid physiological stress.

In this study, we aimed to characterise NLR across a range of ICD-10 (World Health Organisation, 1992) psychiatric diagnoses and to investigate the relationship between NLR and adverse clinical outcomes.

Methods

Variables

Demographics

Demographic variables were retrieved from structured fields in the CRIS database and included age at earliest blood test, gender and ethnicity. Ethnicity was coded using ONS guidelines (Office for National Statistics, 2009). To facilitate comparison with the NHANES sample, we combined ‘Other’ and ‘Mixed’ ethnicity codes into one category ‘Other/Mixed’.

Neutrophil to lymphocyte ratio

Absolute neutrophil and lymphocyte counts were obtained from routine blood testing data, attained at the point of patient entry to SLaM secondary care services. NLR was calculated for each patient by dividing neutrophil count by lymphocyte count. We extracted earliest available blood count values to minimise potential confounding effects of secondary healthcare treatment.

ICD-10 diagnosis

We included diagnoses from eight ICD-10 diagnostic blocks in this study: Organic, including symptomatic, mental disorders (F01-F09), Mental and behavioural disorders due to psychoactive substance use (F10-F19), Schizophrenia, schizotypal and delusional disorders (F20-F29), mood [affective] disorders (F30-F39), Neurotic, stress-related and somatoform disorders (F40-F49), Behavioural syndromes associated with physiological disturbances and physical factors (F50-59), Disorders of adult personality and behaviour (F60-F69) and Mental retardation (F70-F79). Diagnostic variables were defined by the primary diagnosis assigned to the patient closest to their blood test result.

We excluded patients with diagnoses in the Disorders of psychological development (F80-F89) and Behavioural/emotional disorders with onset usually occurring in childhood and adolescence (F90-F98) diagnostic blocks as most patients were under 16 years old. We also excluded patients in the Unspecified mental disorder (F99) block due to ambiguity of the diagnosis.

Adverse clinical outcomes

We defined ‘number of overnight bed stays’ as the total number of overnight hospital stays for each patient since the date of the blood test. We defined ‘number of face-to-face events’ as the number of clinical face-to-face contacts, such as hospital appointments, for each patient since the date of the blood test. Both measures were adjusted for patient time in services since the date of the blood test. Death was recorded as a dichotomous mortality variable.

Medication

The medication prescribed to the patient within 1 year of the blood test date was extracted. Medications were categorised into four classes: antipsychotics, antidepressants, mood stabilisers and hypnotics.

Statistical Analysis

We conducted all statistical analyses for this study using R (version 3.6). We analysed data distribution by use of histogram. We report the mean and standard deviation (SD) for normally distributed data.

Because NLR data demonstrated an exponential distribution (see Figures 1 and 2),we conducted regression analyses using a log-linked gamma-family generalised linear model. For each analysis, the shape parameter of the model was estimated using the gamma.shape function from the MASS package, and this was used to set the dispersion parameter as 1/(maximum likelihood estimate). We ran the following models: 1) Control NLR as dependent variable vs. NLR in ICD-10 diagnoses; 2) NLR between all ICD-10 diagnoses that were significantly different from control NLR from Model 1. In Models 1 and 2 age, ethnicity, gender and medication were included as independent variables. We then ran three separate models within the CRIS dataset only to investigate the association of NLR with clinical outcome measures. These models set NLR as the dependent variable vs death, hospital admissions or numbers of face-to face contact. ICD-10 diagnosis, age, ethnicity, gender and medication were included as independent variables.

• Download figure
• Open in new tab

Figure 1:

Distribution of Neutrophil to Lymphocyte Ratio (NLR) in patient sample

• Download figure
• Open in new tab

Figure 2:

Distribution of Neutrophil to Lymphocyte Ratio (NLR) in control sample

Results

Model 1: NLR between controls and patients

NLR in the following ICD-10 diagnoses were significantly higher than controls: F00, Alzheimer’s disease (β = 0.15, p = 1.3e-06); F01, vascular dementia (β = 0.24, p = 0.003); F02 dementia in other diseases (β = 0.27, p = 0.008); F05, delirium (β =0.28, p = 0.003); F06, other mental disorders due to brain damage and dysfunction (β = 0.16, p = 0.0006); F10, mental and behavioural disorders due to alcohol (β = 0.16, p = 2.0e-14); F20, schizophrenia (β = 0.09, p = 9.7e-08); F23, acute and transient psychotic disorders (β = 0.16, p = 3.7e-08); F25, schizoaffective disorders (β = 0.07, p = 0.002); F28, other nonorganic psychotic disorders (β = 0.17, p = 0.03); F29, unspecified nonorganic psychotic disorders (β = 0.13, p = 1.9e-07); F30, manic episode (β = 0.20, p = 3.0e-06); F31, bipolar affective disorder (β = 0.12, p = 3.0e-07); F32, depressive episode (β = 0.13, p =7.31e-11); F33, recurrent depressive disorder (0.14, p = 7.9e-07); F38 other mood [affective] disorders (β = 0.41, p = 0.001); F41, other (non-phobic) anxiety disorders (β = 0.06, p =0.03); F43, reaction to severe stress, and adjustment disorders (β = 0.08, p = 0.004); F60, specific personality disorders (β = 0.09, p = 0.0005); F61, mixed personality disorders (β = 0.18, p = 0.03); F70, mild mental retardation (β = 0.14, p = 0.02) and F79, unspecified mental retardation (β = 0.40, p = 0.047). There were no diagnoses with NLR significantly lower than controls. In the model, age was also positively correlated with NLR (β = 0.005, p < 2e-16; Figure 3). Black ethnicity was associated with lower NLR (β = −0.23, p < 2e-16) and White ethnicity with higher NLR (β = 0.09, p = 5.8e-07; Figure 4). Antipsychotic use (β = 0.04, p = 0.003)) and hypnotic use (β = 0.03, p = 0.01) were both associated with higher NLR (see supplementary materials table T1).

• Download figure
• Open in new tab

Figure 3:

Neutrophil to Lymphocyte Ratio (NLR) (uncorrected) across ethnicity

• Download figure
• Open in new tab

Figure 4:

Neutrophil to Lymphocyte Ratio (NLR) (uncorrected) across age groups

Discussion

This study suggests that systemic inflammation occurs in several psychiatric diagnoses. In particular, NLR elevation was seen in patients with dementia, alcohol dependence, schizophrenia, bipolar affective disorder, depression, non-phobic anxiety disorders, and mild mental retardation. In those groups with elevated NLR, the only diagnostic group that had significantly higher NLR was F38 “other mood disorders”. All other diagnoses with elevated NLR did not significantly differ in terms of NLR level, suggesting that NLR elevation is a non-specific, cross-diagnostic finding. It is possible that patients with elevated NLR have a shared inflammatory aetiology to their different clinical presentations.

In comparing our findings to published data, one previous study of NLR found that patients with acute schizophrenia had higher NLR than patients with manic phase BD (Ozdin et al, 2017), whereas Mazza and colleagues (2019b) did not find any difference in NLR between patients with bipolar and unipolar depression. Another group reported that NLR was elevated in patients with Alzheimer’s disease compared to age-matched patients with MDD and Parkinson’s disease (Baykan et al. 2018). We did not find any evidence for elevated NLR in Alzheimer’s disease compared to other diagnoses, but we were not able to exclude the possibility that NLR elevations may occur during acute exacerbations of psychosis.

Our results align closely with findings from other inflammatory biomarkers. A recent meta-analysis indicated variation patterns in inflammatory biomarkers IL-6, TNF and CRP were comparable across diagnoses (Pinto et al, 2017). Thus, current evidence suggests that phenomenologically defined diagnostic criteria do not map closely onto biologically-based pathogenic markers such as NLR (Zachar & Kendler, 2017).

In terms of the association of NLR with patient outcomes, we found a significant positive relationship been NLR and mortality but we found no relationship between NLR and ‘number of overnight bed stays’ or ‘number of face-to-face events’. A previous study investigated a similar clinical outcome measure ‘number of hospitalisations’ and found a positive relationship with NLR in patients with BD (Melo et al, 2019). The study involved a small sample of 80 patients, but the findings were strengthened by the fact the authors employed a longitudinal design. The difference in findings with our study could be due to the cross-diagnostic nature of our study, and the fact that the patients were not all in-patients.

A positive relationship between mortality and NLR has been indicated across physical health disorders (Afari & Bhat, 2016, Koh et al, 2015, Templeton et al, 2014). As we were not able to adjust for physical health comorbidities, the relationship that we found may reflect an association between systemic inflammation and poor physical health. Alternatively, our findings may reflect an independent positive relationship between NLR and mortality in psychiatric patients. In both BD patients and MDD patients, NLR has been found to be a significant predictor of suicide risk (Ekinci & Ekinci, 2017, Ivkovic et al, 2016), which may account for some of the increased mortality. However, elevated NLR has been found to independently predict mortality, irrespective of age, sex, education, metastatic cancer, liver disease and depression (Isaac et al, 2016) suggesting systemic inflammation may reduce survival through alternative pathological pathways.

Limitations

This study has several limitations. Confounding factors which may modulate NLR such as body mass index (Azab et al, 2014), smoking (Tulgar et al, 2016), diet and exercise (Gialluisi et al, 2019) were not controlled for and so interactions such as a positive correlation between depression and obesity (Luppino et al, 2010, Mannan et al, 2016) may have confounded our results. Likewise, comorbid physical conditions found to modulate NLR, such as cancer or autoimmune disease (Bhat et al, 2013, Celikbilek et al, 2013, Templeton et al, 2014), were neither excluded nor adjusted for.

The control sample represents a non-institutionalised civilian (US) population. These participants were not screened for physical or mental disorders, so the prevalence of these conditions in the control sample is unknown. The fact that samples were selected from different countries and blood cell essays were performed in different laboratories reduces the validity of our patient and control comparisons. However, although NLR was elevated in some ICD-10 diagnoses compared to the control group, NLR in patients with other diagnoses did not significantly differ from this control sample, suggesting that the control NLR was suitable as a comparison group in this study.

This study did not employ validated symptom severity measures. ‘Number of overnight bed stays’ and ‘number of face-to-face events’ are logical outcome measures of illness severity. These real-world measures increased the clinical transferability of our results, but they may be affected by unknown factors, such as help-seeking attitudes or illness insight.

This sample is representative of a population seeking secondary care services. Results may not be generalisable to patients seeking primary care services. Finally, this is a cross-sectional study, so causal inferences cannot be inferred.

Nonetheless, this is the largest study to date of cross-diagnostic NLR measurements in a psychiatric population and our sample is representative of adult psychiatric patients in South London. Every patient who accessed SLaM services within our time frame and had available blood count data from age 16 years old or above, was included in our sample. This minimised selection biases. Previous studies included only elderly (Baykan et al, 2018) or Caucasian patients (Mazza et al, 2019b) and so were less generalisable. Our sample is diverse in age and ethnicity so demonstrates improved translational potential. This study also compares NLR across the broadest range of diagnoses to date and employs the largest sample yet to address these two research aims.

Future Directions

Findings suggest broad transdiagnostic commonalities regarding systemic inflammation. As within-diagnostic differences in inflammation have also been found (Raison & Miller, 2011, Lamers et al, 2013), it appears inflammatory processes are not bound to traditional diagnostic categories. In both depression and schizophrenia, inflammation is thought to contribute to treatment resistance (Mondelli et al, 2015, Lanquillion, Krieg, Bening-Abu-Shach & Vedder, 2000), perhaps contributing to poor primary treatment response rates in psychiatry (Gaynes et al, 2008, Tiihonen et al, 2017).

It may be fruitful for future studies investigating NLR in psychiatric populations to employ a Research Domain Criteria (RDoC) approach (Cuthbert & Insel, 2010). RDoC reconceptualises psychopathology into transdiagnostic domains, presenting a novel classification of mental illnesses, based on dimensions of observable behaviour and neurobiological measures (Morris & Cuthbert, 2012). As our results indicate inflammatory processes are shared across diagnoses, inflammation may play a role in symptom domains shared by these conditions. For example, alterations in serotonergic, dopaminergic and glutamatergic pathways are consistently reported across mood (Ashok et al, 2017, Cowen, 2008, Werner et al, 2010) and psychotic (Guillin et al, 2007, Stone et al, 2007) disorders and have been reported to be mediated by immunological pathways (Miller, 2009, Miller et al, 2013, Müller & Schwarz, 2007). Immune-mediated alterations in serotoninergic and glutamatergic systems may result in mood and cognitive symptoms whilst inflammation-induced modifications of dopaminergic systems may result in motivational changes (Capuron & Castanon, 2016).

NLR may be a useful and cost-effective transdiagnostic parameter by which to stratify psychiatric patients on a common pathophysiological basis. Recent years have seen pharmaceutical companies withdraw investments from psychiatry due to ‘low probability of success’ (Miller, 2010) and nosology has been highlighted as one of the barriers to research progress (Fibiger et al, 2012). Transdiagnostic biological abnormalities may constitute common targets for pharmacological treatment and NLR may be an accessible tool to aid in identification and stratification of these patients in clinical trials.

Conclusions

Systemic inflammation may occur as a transdiagnostic pathological process in a subpopulation of psychiatric patients. NLR may be an effective biomarker to identify these patients who may benefit from adjunctive anti-inflammatory pharmacological treatment.

Author Statement

The study was conceived by JS with further development by AB. Data extraction was by AB and was specified by JS. Literature review, data analysis first draft of the manuscript was by AB with supervision by JS. Both authors contributed to manuscript preparation and approved the final version.